Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study

被引：0
作者：
Mei Li
Zhenlin Zhang
Qingyun Xue
Qifu Li
Xiaolan Jin
Jin Dong
Qun Cheng
Li You
Hua Lin
Hai Tang
Lin Shen
Xin Gao
Ji Hu
Aijun Chao
Pengqiu Li
Rui Shi
Shuhui Zheng
Ying Zhang
Xiaojiang Xiong
Wei Yu
Weibo Xia
机构：
[1] Chinese Academy of Medical Sciences,Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital
[2] Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Department of Osteoporosis and Bone Disease
[3] Beijing Hospital,Department of Orthopaedics
[4] National Center of Gerontology,Department of Endocrinology
[5] The First Affiliated Hospital of Chongqing Medical University,Department of Endocrinology
[6] Western Theater Command General Hospital,Department of Endocrinology
[7] The First Affiliated Hospital of Shanxi Medical University,Department of Osteoporosis and Bone Disease
[8] Huadong Hospital Affiliated to Fudan University,Department of Endocrinology and Metabolism, Shanghai General Hospital
[9] Shanghai Jiao Tong University,Department of Orthopaedics, Nanjing Drum Tower Hospital
[10] The Affiliated Hospital of Nanjing University Medical School,Department of Orthopedics, Beijing Friendship Hospital
[11] Capital Medical University,Department of Integrated of Traditional Chinese and Western Medicine, Union Hospital
[12] Tongji Medical College of Huazhong University of Science and Technology,Department of Endocrinology, Zhongshan Hospital
[13] Fudan University,Department of Obstetrics and Gynecology
[14] The Second Affiliated Hospital of Soochow University,Department of Orthopaedics
[15] Tianjin Hospital,Department of Endocrinology
[16] Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital,Department of Orthopedics, West China Hospital
[17] Sichuan University,Department of Orthopaedics
[18] Heibei General Hospital,Department of Endocrinology
[19] The Third Affiliated Hospital of Guangzhou Medical University,Department of Orthopedics Joint Disease Area
[20] Chongqing Three Gorges Central Hospital,Department of Radiology, Peking Union Medical College Hospital
[21] Chinese Academy of Medical Sciences,Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
[22] Chinese Academy of Medical Sciences,undefined
来源：
Archives of Osteoporosis | 2022年 / 17卷
关键词：
Teriparatide; Alendronate; Postmenopausal osteoporosis; Bone mineral density; Bone turnover markers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 157 条
  • [11] Zhou RJ(2000)The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study Calcif Tissue Int 67 286-448
  • [12] Feng XL(2009)The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis J Bone Miner Metab 27 471-4535
  • [13] Compston JE(2011)Teriparatide vs alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life Med Sci Monit 17 Cr442-288
  • [14] McClung MR(2002)A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 4528-502
  • [15] Leslie WD(2016)The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment Calcif Tissue Int 99 282-673
  • [16] Yuan F(2010)Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases Bone 47 493-1845
  • [17] Peng W(2019)Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE Osteoporos Int 30 667-775
  • [18] Yang C(2010)Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis J Clin Endocrinol Metab 95 1838-339
  • [19] Zheng J(2019)Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial Lancet Diabetes Endocrinol 7 767-1226
  • [20] Camacho PM(2007)Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326-1768
12345678910